Haematologica (Aug 2024)

Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations

  • Caroline S. Myers,
  • Eli Williams,
  • Carlos Barrionuevo Cornejo,
  • Georgios Pongas,
  • Ngoc L. Toomey,
  • Jose A. Sanches,
  • Maxime Battistella,
  • Samuel Mo,
  • Melissa Pulitzer,
  • Cristopher A. Moskaluk,
  • Govind Bhagat,
  • Kenneth Ofori,
  • Jonathan J. Davick,
  • Octavio Servitje,
  • Denis Miyashiro,
  • Fina Climent,
  • Kimberley Ringbloom,
  • Daniela Duenas,
  • Calvin Law,
  • Sandro Casavilca Zambrano,
  • Luis Malpica,
  • Brady E. Beltran,
  • Denisse Castro,
  • Luciana Barreto,
  • Carlos Brites,
  • Jennifer R. Chapman,
  • Jaehyuk Choi,
  • Alejandro A. Gru,
  • Juan C. Ramos

DOI
https://doi.org/10.3324/haematol.2024.285233
Journal volume & issue
Vol. 999, no. 1

Abstract

Read online

Adult T-cell leukemia-lymphoma (ATLL) is an aggressive Human T-cell Leukemia Virus Type 1 (HTLV-1)-driven malignancy. Although Western hemisphere (Afro-Caribbean and South American) patients face worse prognoses, our understanding of ATLL molecular drivers derives mostly from Japanese studies. We performed multi-omic analyses to elucidate the genomic landscape of ATLL in Western cohorts. Recurrent deletion and/or damaging mutations involving FOXO3, ANKRD11, DGKZ, and PTPN6 implicate these genes as potential tumor suppressors. RNA-seq, published functional data and in vitro assays support the roles of ANKRD11 and FOXO3 as regulators of T-cell proliferation and apoptosis in ATLL, respectively. Survival data suggest ANKRD11 mutation may confer a worse prognosis. Japanese and Western cohorts, in addition to acute and lymphomatous subtypes, demonstrated distinct molecular patterns. GATA3 deletion was associated with unfavorable chronic cases. IRF4 and CARD11 mutations frequently emerged in relapses after interferon therapy. Our findings reveal novel putative ATLL driver genes and clinically relevant differences between Japanese and Western ATLL patients.